| Patents for C12Q 1 - Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions (300,231) |
|---|
| 05/06/2004 | WO2004038377A2 Method for diagnosing renal diseases or predispositions |
| 05/06/2004 | WO2004038372A2 Cdkl1 as modifier of branching morphogenesis and methods of use |
| 05/06/2004 | WO2004038371A2 Ccr8 as modifier of branching morphogenesis and methods of use |
| 05/06/2004 | WO2004038370A2 Enhancing the sensitivity of a microsphere sensor |
| 05/06/2004 | WO2004038369A2 Ip3 protein binding assay |
| 05/06/2004 | WO2004038368A2 Device and method for monitoring leukocyte migration |
| 05/06/2004 | WO2004038367A2 Biological assays using gradients formed in microfluidic systems |
| 05/06/2004 | WO2004038366A2 ISOTHERMAL AMPLIFICATION BASED ASSAY FOR THE DETECTION AND QUANTITATION OF ALPHA-FETOPROTEIN mRNA |
| 05/06/2004 | WO2004038045A2 Method for diagnosing diffuse-type gastric cancer |
| 05/06/2004 | WO2004038044A1 Kit of reagents for the identification of biological contaminants in a sample |
| 05/06/2004 | WO2004038043A2 POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS |
| 05/06/2004 | WO2004038041A1 Screening assay to identify inhibitors of the murd enzyme using an activator-independent murd enzyme |
| 05/06/2004 | WO2004038040A2 Enzyme array and assay |
| 05/06/2004 | WO2004038038A2 Amplicon melting analysis with saturation dyes |
| 05/06/2004 | WO2004038037A2 Controlled alignment of nano-barcodes encoding specific information for scanning probe microscopy (spm) reading |
| 05/06/2004 | WO2004038036A2 Methods of assaying for modulators of the inflammatory process using components of the ubiquitin ligation cascade |
| 05/06/2004 | WO2004038035A1 Process for producing fructosyl valine and method of quantifying fructosyl valine obtained thereby |
| 05/06/2004 | WO2004038034A1 Novel fructosyl peptide oxidase and utilization thereof |
| 05/06/2004 | WO2004038033A1 Defructosylation method |
| 05/06/2004 | WO2004038022A1 Method of examining swine genetic resistance to rna virus-origin disease |
| 05/06/2004 | WO2004038007A2 Dna polymerases with reduced base analog detection activity |
| 05/06/2004 | WO2004037997A2 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof |
| 05/06/2004 | WO2004037992A2 Mapk7 as modifier of branching morphogenesis and methods of use |
| 05/06/2004 | WO2004037991A2 Prkcb1 as modifier of branching morphogenesis and methods of use |
| 05/06/2004 | WO2004037989A2 Modified nucleotides and methods of labeling nucleic acids |
| 05/06/2004 | WO2004037988A2 Methods for synthesizing complementary dna |
| 05/06/2004 | WO2004037986A2 Map2k6 as modifier of branching morphogenensis and methods of use |
| 05/06/2004 | WO2004037984A2 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2004 | WO2004037977A2 Use of chimeric nucleases to stimulate gene targeting |
| 05/06/2004 | WO2004037975A2 Composition and method for imaging cells |
| 05/06/2004 | WO2004037972A2 Endogenous retrovirus up-regulated in prostate cancer |
| 05/06/2004 | WO2004037907A2 Luminescent metal ion complexes |
| 05/06/2004 | WO2004037852A2 Thymidylate synthase polymorphisms for use in screening for cancer susceptibility |
| 05/06/2004 | WO2004037848A2 Process for determining target function and identifying drug leads |
| 05/06/2004 | WO2004037385A1 A filter device integrating sampled volume control |
| 05/06/2004 | WO2004037380A1 A reception head for a filter unit |
| 05/06/2004 | WO2004037371A2 Assay for determining the activity of fatty acid amide hydrolase |
| 05/06/2004 | WO2004037282A1 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| 05/06/2004 | WO2004037251A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 05/06/2004 | WO2004037200A2 Reticulocyte depletion signatures |
| 05/06/2004 | WO2004037192A2 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases |
| 05/06/2004 | WO2004037175A2 Compositions and methods for treating human papillomavirus-mediated disease |
| 05/06/2004 | WO2004037160A2 In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound |
| 05/06/2004 | WO2004024945A3 Method for the non-invasive detection of microorganisms in a closed container |
| 05/06/2004 | WO2004017895A3 Formaldehyde-ammonium salt complexes for the stabilization of blood cells |
| 05/06/2004 | WO2004015416A3 Methods for the identification of agents with anti-microbial action |
| 05/06/2004 | WO2004013629A3 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases |
| 05/06/2004 | WO2004010074A3 Biosensor arrays and methods |
| 05/06/2004 | WO2004009787A3 Method and apparatus for manipulating polarizable analytes via dielectrophoresis |
| 05/06/2004 | WO2004007755A9 Multiplex nucleic acid reactions |
| 05/06/2004 | WO2004005918A3 Characterization of biochips containing self-assembled monolayers with maldi-tof-ms |
| 05/06/2004 | WO2004005484A3 Snrks as modifiers of chk and branching morphogenesis and methods of use |
| 05/06/2004 | WO2004003562A3 Oncolytic viruses as phenotyping agents for neoplasms |
| 05/06/2004 | WO2004001068A3 Use of pp2a phosphatase modulators in the treatment of mental disorders |
| 05/06/2004 | WO2003106631A3 Methods and compositions relating to labeled rna molecules that reduce gene expression |
| 05/06/2004 | WO2003102154A3 Improved receptor detection |
| 05/06/2004 | WO2003102141A3 Identification of a gene causing the most common form of bardet-biedl syndrome and uses thereof |
| 05/06/2004 | WO2003100028A3 Tr2, tr4, tr2/tr4 double knockouts and uses thereof |
| 05/06/2004 | WO2003099997A3 Methods and compositions for regulation and manipulation of steroidogenesis |
| 05/06/2004 | WO2003099318A3 Pancreas-specific proteins |
| 05/06/2004 | WO2003096964A3 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac |
| 05/06/2004 | WO2003093414A3 Transgenic animal model for spliceosome-mediated rna trans-splicing |
| 05/06/2004 | WO2003091382A3 Dna authentication based on scattered-light detection |
| 05/06/2004 | WO2003090695A3 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY |
| 05/06/2004 | WO2003089922A8 Method for detecting ligands and targets in a mixture |
| 05/06/2004 | WO2003088910A3 Methods of assaying for cell cycle modulators |
| 05/06/2004 | WO2003074671A3 Mbcats as modifiers of the beta-catenin pathway and methods of use |
| 05/06/2004 | WO2003072801A3 Compositions and method for regulation of calcium-dependent signalling in brain |
| 05/06/2004 | WO2003064469A8 Regulation of human hematopoietin receptor-like protein |
| 05/06/2004 | WO2003048377A3 Multiplex real-time quantitative pcr |
| 05/06/2004 | WO2003031567A9 Precursor conversion screening methods |
| 05/06/2004 | WO2003027631A3 Muscle sample prepared for prion assay |
| 05/06/2004 | WO2003025575A8 Methods and compositions involving thymidine phosphorylase as a marker for hiv infection, aids progression, and drug resistance |
| 05/06/2004 | WO2002101091A3 Method for detecting and identifying the presence of biological materials derived from fish, and oligonucleotides therefor |
| 05/06/2004 | WO2002092788A9 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| 05/06/2004 | WO2002088078A3 INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES |
| 05/06/2004 | WO2002087510A3 Subcellular targeting of therapeutic proteins |
| 05/06/2004 | WO2002075609A9 Predicting metabolic stability of drug molecules |
| 05/06/2004 | WO2002042735A3 Human kcr1 regulation of herg potassium channel block |
| 05/06/2004 | WO2002038108A3 Methods of treating disorders related to apoe |
| 05/06/2004 | US20040088757 Comprises monopartite RNA viral vector for transformation and expression of heterologous genes in plants |
| 05/06/2004 | US20040088756 Identifying diseases resistance gene in plants |
| 05/06/2004 | US20040087784 Neuronal serine-threonine protein kinase |
| 05/06/2004 | US20040087782 Nucleotide sequences for detecting protein antigen b (PAB) gene sequences and diagnosing mycobacterium infection |
| 05/06/2004 | US20040087770 Viral peptide for use in diagnosing, preventing and treating sepsis and meningitis; microbiocides; vaccine development |
| 05/06/2004 | US20040087538 Nucleic acids containing unmethylated cytosine-guanine dinucleotides activate lymphocytes and redirect an immune response from th2 to th1 |
| 05/06/2004 | US20040087534 2-100 nucleotides containing >/= 1 unmethylated cytosine-guanine dinucleotide; antisense therapies; in vivo hybridization probes; viricides |
| 05/06/2004 | US20040087532 Vaccine comprising antigen presenting cells loaded with at least two tumor antigens and/or tumor antigen derived peptides |
| 05/06/2004 | US20040087489 Compositions and methods for the treatment of mycobacterial infections |
| 05/06/2004 | US20040087478 Discovering pain regulating substances; incubating with then measuring binding to cell synthesized peptide or protein |
| 05/06/2004 | US20040087032 Microparticles with multiple fluorescent signals and methods of using same |
| 05/06/2004 | US20040087023 Methods of determining deficiencies in intracellular levels of cysteine and glutathione |
| 05/06/2004 | US20040087016 Using cyclin dependent kinase inhibitors to return differentiated cells to pluripotent state; tissue engineering and organ transplantation |
| 05/06/2004 | US20040087014 Eukaryotic expression libraries and methods of use |
| 05/06/2004 | US20040087012 Nucleus export reporter system |
| 05/06/2004 | US20040087007 System and method for optimizing tissue barrier transfer of compounds |
| 05/06/2004 | US20040086988 Enzyme catalyst; polypeptides; crystal structure |
| 05/06/2004 | US20040086975 Comprises adenoid expressed chemokine for modulating, treating and diagnosing abnormalities in inflamed or diseased tissues |
| 05/06/2004 | US20040086973 Calmodulin-dependent protein kinase inhibitor for treatment and prevention of nervous system disorders |
| 05/06/2004 | US20040086959 Using in vitro translation to generation heterologous proteins; bioreactors |